National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 8, 2015, Pages 1343-1359

  Martin, Paul J ^a   Lee, Stephanie J ^a   Przepiorka, Donna ^b   Horowitz, Mary M ^c   Koreth, John ^d   Vogelsang, Georgia B ^e   Walker, Irwin ^f   Carpenter, Paul A ^a   Griffith, Linda M ^g   Akpek, Gorgun ^h   Mohty, Mohamad ⁱ   Wolff, Daniel ^j   Pavletic, Steven Z ^k   Cutler, Corey S ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h Banner MD Anderson Cancer Center   (United States)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j UNIVERSITY OF REGENSBURG   (Germany)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Allogeneic hematopoietic cell transplantation; Chronic graft versus host disease; Clinical trials; Consensus; Design; Guidelines

Indexed keywords

CYCLOSPORIN; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; FAILURE FREE SURVIVAL; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSTITUTIONAL REVIEW; NATIONAL HEALTH ORGANIZATION; OVERALL SURVIVAL; REVIEW; SELF REPORT; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; GRAFT VS HOST DISEASE; HISTORY; PROCEDURES; UNITED STATES;

CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HISTORY, 21ST CENTURY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 84937709873     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.004     Document Type: Review

References (73)

1. Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Available at: http://www.cibmtr.org.
2. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
3. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
4. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft- versus-host disease. Biol Blood Marrow Transplant 2001, 7:265-273.
5. Gilman A.L., Schultz K.R., Goldman F.D., et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study. Biol Blood Marrow Transplant 2012, 18:84-91.
6. Koc S., Leisenring W., Flowers M.E., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000, 96:3995-3996.
7. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100:48-51.
8. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
9. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
10. Flowers M.E., Apperley J.F., van Besien K., et al. Amulticenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008, 112:2667-2674.
11. Greinix H.T., van Besien K., Elmaagacli A.H., et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2011, 17:1775-1782.
12. Martin P.J., Inamoto Y., Carpenter P.A., et al. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol 2011, 46:153-163.
13. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. VI. Design of Clinical Trials Working Group Report. Biol Blood Marrow Transplant 2006, 12:491-505.
14. Jagasia M.H., Greinix H.T., Arora M., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2015, 21:389-401.
15. Shulman H.M., Cardona D.M., Greenson J.K., et al. NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015, 21:589-603.
16. Paczesny S., Hakim F.T., Pidala J., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant 2015, 21:780-792.
17. Carpenter P.A., Kitko C.L., Elad S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015, 21:1343-1359.
18. Lee S.J., Wolff D., Kitko C., et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant 2015, 21:984-999.
19. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
20. Wolff D., Gerbitz A., Ayuk F., et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010, 16:1611-1628.
21. Wolff D., Schleuning M., von Harsdorf S., et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1-17.
22. Flowers M.E., Martin P.J. How we treat chronic graft-versus-host disease. Blood 2015, 125:606-615.
23. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
24. Inamoto Y., Storer B.E., Lee S.J., et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood 2013, 121:2340-2346.
25. Pidala J., Tomblyn M., Nishihori T., et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica 2011, 96:1351-1356.
26. Inamoto Y., Martin P.J., Storer B.E., et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica 2014, 99:1618-1623.
27. Mitchell S.A., Jacobsohn D., Thormann Powers K.E., et al. Amulticenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: Feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant 2011, 17:1619-1629.
28. Jacobsohn D.A., Kurland B.F., Pidala J., et al. Correlation between NIHcomposite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012, 120:2545-2552.
29. Inamoto Y., Chai X., Kurland B.F., et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012, 119:487-493.
30. Treister N., Chai X., Kurland B., et al. Measurement of oral chronic GVHD: Results from the Chronic GVHD Consortium. Bone Marrow Transplant 2013, 48:1123-1128.
31. Palmer J., Williams K., Inamoto Y., et al. Pulmonary symptoms measured by the National Institutes of Health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:337-344.
32. Inamoto Y., Pidala J., Chai X., et al. Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheum 2014, 66:1044-1052.
33. Bassim C.W., Fassil H., Mays J.W., et al. Validation of the National Institutes of Health chronic GVHD oral mucosal score using component-specific measures. Bone Marrow Transplant 2014, 49:116-121.
34. Curtis L.M., Grkovic L., Mitchell S.A., et al. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. Bone Marrow Transplant 2014, 49:1513-1520.
35. Yanik G.A., Mineishi S., Levine J.E., et al. Soluble tumor necrosis factor receptor: Enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1044-1054.
36. Olivieri A., Cimminiello M., Corradini P., et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013, 122:4111-4118.
37. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant 2006, 12:252-266.
38. Inamoto Y., Martin P.J., Chai X., et al. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:1517-1524.
39. Palmer J.M., Lee S.J., Chai X., et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:1649-1655.
40. Martin P.J., Storer B.E., Carpenter P.A., et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 17:124-132.
41. Inamoto Y., Flowers M.E., Sandmaier B.M., et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 2014, 124:1363-1371.
42. Flowers M.E., Storer B., Carpenter P., et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:1380-1384.
43. Guidance for industry: Clinical trial endpoints the approval of cancer drugs and biologics. Retrieved from. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf.
44. Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Retrieved from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
45. Lee S., Cook E.F., Soiffer R., Antin J.H. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:444-452.
46. Jacobsohn D.A., Rademaker A., Kaup M., Vogelsang G.B. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD. Bone Marrow Transplant 2009, 44:813-819.
47. Williams L.A., Couriel D.R., Mendoza T.R., et al. Anew measure of symptom burden in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:S177. (abstract).
48. PROMIS. Dynamic tools to measure health outcomes from the patient perspective. Retrieved from Accessed February 23,2014. http://www.nihpromis.org.
49. Ware J.E., Kosinski M., Keller S.D. SF-36 physical and mental health summary scales: A user's manual 1994, The Health Institute, New England Medical Center, Boston, MA.
50. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 health survey: A manual and interpretation guide 1993, The Health Institute, New England Medical Center, Boston, MA.
51. McQuellon R.P., Russell G.B., Cella D.F., et al. Quality of life measurement in bone marrow transplantation: Development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997, 19:357-368.
52. McQuellon R.P., Russell G.B., Rambo T.D., et al. Quality of life and psychological distress of bone marrow transplant recipients: The "time trajectory" to recovery over the first year. Bone Marrow Transplant 1998, 21:477-486.
53. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006, 38:305-310.
54. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: Report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.
55. Pidala J., Kurland B.F., Chai X., et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: Results from the Chronic Graft-versus-Host Disease Consortium. Haematologica 2011, 96:1528-1535.
56. Walker I., Schultz K.R., Toze C.L., et al. Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: CBMTG 0801, a randomized, controlled trial. Blood 2014, 124:38. (abstract).
57. Bombardier C., Gladman D.D., Urowitz M.B., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
58. Furie R., Petri M., Zamani O., et al. Aphase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
59. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. JRheumatol 2002, 29:288-291.
60. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJ Med 1993, 86:447-458.
61. Liang M.H., Socher S.A., Larson M.G., Schur P.H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 32:1107-1118.
62. Luijten K.M., Tekstra J., Bijlsma J.W., Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI): A new SLE disease activity assessment. Autoimmun Rev 2012, 11:326-329.
63. Vitali C., Bencivelli W., Isenberg D.A., et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10:541-547.
64. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
65. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. Areview of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
66. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
67. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
68. Felson D.T., Smolen J.S., Wells G., et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413.
69. Boers M., Idzerda L., Kirwan J.R., et al. Toward a generalized framework of core measurement areas in clinical trials: A position paper for OMERACT 11. JRheumatol 2014, 41:978-985.
70. Kirwan J.R., Boers M., Tugwell P. Updating the OMERACT filter at OMERACT 11. JRheumatol 2014, 41:975-977.
71. Downing N.S., Aminawung J.A., Shah N.D., et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014, 311:368-377.
72. Sacks L.V., Shamsuddin H.H., Yasinskaya Y.I., et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 2014, 311:378-384.
73. Goodman S.N., Redberg R.F. Opening the FDA black box. JAMA 2014, 311:361-363.